Granules India (GRANULES) Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for GRANULES from our risk checks.
GRANULES Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Granules India Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹813.25 |
| 52 Week High | ₹804.30 |
| 52 Week Low | ₹432.60 |
| Beta | 0.065 |
| 1 Month Change | 5.09% |
| 3 Month Change | 29.48% |
| 1 Year Change | 66.26% |
| 3 Year Change | 175.07% |
| 5 Year Change | 141.89% |
| Change since IPO | 7,708.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| GRANULES | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.2% | 2.2% | -1.5% |
| 1Y | 66.3% | 11.3% | -2.9% |
Return vs Industry: GRANULES exceeded the Indian Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: GRANULES exceeded the Indian Market which returned -2.9% over the past year.
Price Volatility
| GRANULES volatility | |
|---|---|
| GRANULES Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: GRANULES has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: GRANULES's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 4,066 | Krishna Chigurupati | www.granulesindia.com |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions.
Granules India Limited Fundamentals Summary
| GRANULES fundamental statistics | |
|---|---|
| Market cap | ₹198.65b |
| Earnings (TTM) | ₹5.95b |
| Revenue (TTM) | ₹53.66b |
Is GRANULES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRANULES income statement (TTM) | |
|---|---|
| Revenue | ₹53.66b |
| Cost of Revenue | ₹18.76b |
| Gross Profit | ₹34.90b |
| Other Expenses | ₹28.95b |
| Earnings | ₹5.95b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.01 |
| Gross Margin | 65.04% |
| Net Profit Margin | 11.09% |
| Debt/Equity Ratio | 26.3% |
How did GRANULES perform over the long term?
See historical performance and comparisonDividends
Does GRANULES pay a reliable dividends?
See GRANULES dividend history and benchmarks| Granules India dividend dates | |
|---|---|
| Ex Dividend Date | Jul 30 2026 |
| Dividend Pay Date | Sep 05 2026 |
| Days until Ex dividend | 29 days |
| Days until Dividend pay date | 66 days |
Does GRANULES pay a reliable dividends?
See GRANULES dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 12:04 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Granules India Limited is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harith Ahamed | Avendus Spark |
| Cyndrella Carvalho | Centrum Broking Limited |
| Rashmi Sancheti Shetty | CGS International |